Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Pediatr ; 221: 138-144.e3, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32171558

RESUMEN

OBJECTIVES: To characterize primary care providers' (PCPs) practice patterns for atopic dermatitis (AD) in children <2 years old and determine the need for AD guidelines for PCPs focused on this age group. STUDY DESIGN: This is a mixed-methods study consisting of a survey and a retrospective medical record review of PCP practices in the Chicago metropolitan area. The survey was analyzed using both quantitative and qualitative methods. RESULTS: In the survey (n = 52 respondents), PCPs reported management of AD is different in children <2 years compared with older children (88%). They were more likely to refer to a specialist (65%) and less likely to use high-potency topical corticosteroids (64%). In the chart review, PCP visits for children 2-5 years old (n = 50 914) vs those <2 years old (n = 71 913) for AD, older children had medium- and high-potency topical corticosteroids prescribed more frequently than younger children (0.66% vs 0.37%, P < .01 and .15% vs 0.05%, P < .01, respectively). In the subset of children <2 years of age who also were evaluated by a specialist (n = 109), medium- and high-potency topical corticosteroids were prescribed disproportionately at visits to providers in dermatology (57%) vs allergy (30%) vs pediatrics (15%) (P < .01). PCPs suggested that guidelines for this age group should include recommendations for preferred corticosteroids (39%), allergy management (35%), referral criteria (22%), and assessment of disease severity (11%). CONCLUSIONS: PCP management of AD in children <2 years is different from older children, with possible underuse of medium/high-potency topical corticosteroids. Clear guidelines for this age group are needed.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/epidemiología , Pediatras , Pautas de la Práctica en Medicina/estadística & datos numéricos , Administración Tópica , Compuestos de Boro/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Inhibidores de la Calcineurina/uso terapéutico , Preescolar , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Glucocorticoides/uso terapéutico , Humanos , Masculino , Atención Primaria de Salud , Derivación y Consulta/estadística & datos numéricos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Estados Unidos/epidemiología
2.
Clin Pediatr (Phila) ; 62(10): 1176-1185, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-36797982

RESUMEN

Atopic dermatitis (AD) is a common skin condition and is undertreated in children under 2 years, whom there are no specific guidelines for. We sought to understand barriers to AD treatment and primary care pediatricians' (PCPs) suggested solutions. We conducted semi-structured focus groups (n = 5) with PCPs (n = 17) on how the undertreatment of AD can be addressed. Data were analyzed using an inductive qualitative approach. Participants noted that the perceived undertreatment of AD in children under 2 years could be explained by topical corticosteroid (TCS) use hesitancy, lack of caregiver adherence to PCP recommendations, and under-documentation of AD in the electronic medical record (EMR). Proposed suggestions for improving AD management included caregiver and PCP education on TCS safety; stepwise management guidelines for this age group; and EMR aids to help document and manage AD. Research is warranted to create and disseminate clinician-friendly AD management guidelines for this age group.


Asunto(s)
Dermatitis Atópica , Niño , Humanos , Lactante , Dermatitis Atópica/tratamiento farmacológico , Grupos Focales , Corticoesteroides , Glucocorticoides , Pediatras
3.
Dermatitis ; 32(1S): S8-S14, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34677167

RESUMEN

Atopic dermatitis (AD) is a heterogeneous disorder with varying phenotypes. Although AD has long been associated with barrier dysfunction, the pathogenesis of this disease is more complex, involving many molecular markers in different functional domains. Biomarkers can be helpful in different ways, including predicting prognosis, measuring treatment response, and gauging disease severity. With the advent of targeted immunomodulators, biomarkers have the potential to take on new significance in terms of selecting appropriate therapies for patients. In this review, we have summarized the key findings related to biomarkers and AD, including the specific subtype differences. Clinicians will use this information to better understand the potential of biomarkers in AD and have a guide because more specific treatments are developed that are tailored toward individual molecular profiles.


Asunto(s)
Alérgenos/metabolismo , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/metabolismo , Medicina de Precisión/métodos , Biomarcadores/metabolismo , Dermatitis Atópica/terapia , Humanos
4.
Clin Dermatol ; 38(3): 360-364, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32563351

RESUMEN

Blemished noses are portrayed in the paintings of such noted artists as Ghirlandaio, Rembrandt, and Andy Warhol. Sometimes, the deformity results from a skin disorder such as rhinophyma as in Ghirlandaio's An Old Man and his Grandson or a saddle nose deformity from congenital syphilis as in Rembrandt's Portrait of Gerard de Lairesse. Andy Warhol's Before and After portrays a large nose before and after cosmetic surgery. This contribution explores some of the lessons that can be learned, both artistically and medically, from these famous works of art.


Asunto(s)
Personajes , Medicina en las Artes , Nariz , Pinturas , Rinofima , Enfermedades de la Piel , Cirugía Plástica , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA